JP2021501214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501214A5 JP2021501214A5 JP2020543729A JP2020543729A JP2021501214A5 JP 2021501214 A5 JP2021501214 A5 JP 2021501214A5 JP 2020543729 A JP2020543729 A JP 2020543729A JP 2020543729 A JP2020543729 A JP 2020543729A JP 2021501214 A5 JP2021501214 A5 JP 2021501214A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- amino acid
- acid sequence
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 77
- 208000024340 acute graft versus host disease Diseases 0.000 claims description 14
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 13
- 239000003053 toxin Substances 0.000 claims description 13
- 231100000765 toxin Toxicity 0.000 claims description 13
- 239000004472 Lysine Substances 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 241000701022 Cytomegalovirus Species 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- HBDJFVFTHLOSDW-DNDLZOGFSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;hydrate Chemical compound O.O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HBDJFVFTHLOSDW-DNDLZOGFSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 229960003017 maltose monohydrate Drugs 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 241000701370 Plasmavirus Species 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- 108020005202 Viral DNA Proteins 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000007979 citrate buffer Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000005847 immunogenicity Effects 0.000 claims description 3
- 229960002160 maltose Drugs 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 5
- 101710182532 Toxin a Proteins 0.000 claims 5
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007420 reactivation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 37
- 238000011282 treatment Methods 0.000 description 25
- 230000002519 immonomodulatory effect Effects 0.000 description 19
- 230000009385 viral infection Effects 0.000 description 12
- 230000007419 viral reactivation Effects 0.000 description 10
- 208000036142 Viral infection Diseases 0.000 description 9
- 208000017760 chronic graft versus host disease Diseases 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 208000000389 T-cell leukemia Diseases 0.000 description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 4
- 206010042971 T-cell lymphoma Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 201000005488 Capillary Leak Syndrome Diseases 0.000 description 2
- 241000701460 JC polyomavirus Species 0.000 description 2
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241001631648 Polyomaviridae Species 0.000 description 2
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1717966.4 | 2017-10-31 | ||
| GBGB1717966.4A GB201717966D0 (en) | 2017-10-31 | 2017-10-31 | Immunotoxins, formulations thereof and their use in medicine |
| PCT/EP2018/079860 WO2019086534A1 (en) | 2017-10-31 | 2018-10-31 | Immunotoxins, formulations thereof and their use in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501214A JP2021501214A (ja) | 2021-01-14 |
| JP2021501214A5 true JP2021501214A5 (enExample) | 2021-12-09 |
| JP7482343B2 JP7482343B2 (ja) | 2024-05-14 |
Family
ID=60580274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543729A Active JP7482343B2 (ja) | 2017-10-31 | 2018-10-31 | 免疫毒素、その製剤、および薬におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11447548B2 (enExample) |
| EP (1) | EP3703748A1 (enExample) |
| JP (1) | JP7482343B2 (enExample) |
| CN (1) | CN111629753B (enExample) |
| AU (1) | AU2018357984B2 (enExample) |
| CA (1) | CA3080873A1 (enExample) |
| GB (1) | GB201717966D0 (enExample) |
| WO (1) | WO2019086534A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717966D0 (en) | 2017-10-31 | 2017-12-13 | Xenikos Bv | Immunotoxins, formulations thereof and their use in medicine |
| EP4289862A4 (en) * | 2020-12-02 | 2025-04-02 | Mabwell (Shanghai) Bioscience Co., Ltd. | Anti-human b7-h3 antibody and application thereof |
| CN112992266B (zh) * | 2021-02-05 | 2021-09-21 | 深圳裕康医学检验实验室 | 一种评估肿瘤免疫耗竭状态的方法、装置和存储介质 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024282452A1 (en) * | 2023-05-30 | 2025-11-27 | Philikos B.V. | Methods and means for the treatment of chronic inflammatory and autoimmune disease |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025091264A1 (zh) * | 2023-10-31 | 2025-05-08 | 成都维瑾柏鳌生物医药科技有限公司 | 一种药物组合物用于制备治疗gvhd的药物的应用 |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808705A (en) * | 1986-12-19 | 1989-02-28 | Cetus Corporation | Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor |
| US4975184A (en) | 1988-01-15 | 1990-12-04 | Henry Filters, Inc. | Horizontal removable pump for filtration systems |
| JPH03504499A (ja) * | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| EP0417193B1 (en) * | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US6372217B1 (en) | 1997-06-03 | 2002-04-16 | Regents Of The University Of Minnesota | Methods for the treatment of CD7+ viral infection with TXU-7-PAP |
| EP0945139A1 (en) | 1998-03-23 | 1999-09-29 | Katholieke Universiteit Nijmegen | Methods and means for the treatment of immune related diseases such as Graft vs. Host disease |
| US20060051355A1 (en) * | 1998-03-23 | 2006-03-09 | Van Oosterhout Ypke V | Methods and means for the treatment of immune-related diseases |
| JP4948174B2 (ja) * | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| US20080233128A1 (en) | 2006-11-02 | 2008-09-25 | Werner Krause | Treatment of Viral Infections |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| WO2009014835A2 (en) | 2007-06-21 | 2009-01-29 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2013066369A2 (en) | 2011-10-03 | 2013-05-10 | The Regents Of The University Of Michigan | Methods for detecting graft-versus-host disease |
| HK1221163A1 (zh) * | 2013-05-02 | 2017-05-26 | Mabxience, S.A. | Tnfr:fc融合多肽的替代配方 |
| GB201717966D0 (en) | 2017-10-31 | 2017-12-13 | Xenikos Bv | Immunotoxins, formulations thereof and their use in medicine |
-
2017
- 2017-10-31 GB GBGB1717966.4A patent/GB201717966D0/en not_active Ceased
-
2018
- 2018-10-31 CN CN201880084645.4A patent/CN111629753B/zh active Active
- 2018-10-31 WO PCT/EP2018/079860 patent/WO2019086534A1/en not_active Ceased
- 2018-10-31 US US16/759,952 patent/US11447548B2/en active Active
- 2018-10-31 JP JP2020543729A patent/JP7482343B2/ja active Active
- 2018-10-31 AU AU2018357984A patent/AU2018357984B2/en active Active
- 2018-10-31 EP EP18803564.6A patent/EP3703748A1/en active Pending
- 2018-10-31 CA CA3080873A patent/CA3080873A1/en active Pending
-
2022
- 2022-08-01 US US17/816,550 patent/US12435138B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501214A5 (enExample) | ||
| US20220169705A1 (en) | Topical application for an anti-hsv antibody | |
| JP2014514346A5 (enExample) | ||
| JP2018515493A5 (enExample) | ||
| CN104487090B (zh) | 一种用于预防或治疗突变型乙型肝炎病毒感染的抗体组合物 | |
| Fouda et al. | Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization | |
| JP2021130668A (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| JP6949012B2 (ja) | Ｂ型肝炎表面抗原に対する抗体及びその使用 | |
| JP7309816B2 (ja) | 結節性痒疹患者における皮膚病変およびそう痒の治療 | |
| CN101878037A (zh) | 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途 | |
| KR20220035483A (ko) | 항-pre-s1 hbv 항체를 이용한 hbv 감염 치료 방법 | |
| CN114729054A (zh) | 使用免疫检查点抑制剂抗体治疗癌症的方法和组合 | |
| JPWO2022037531A5 (enExample) | ||
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| JPWO2020186132A5 (enExample) | ||
| US9657087B2 (en) | Subcutaneous administration of anti-hepatitis B antibodies | |
| CN120000779A (zh) | 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途 | |
| Komlos | American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting (ACR Convergence 2020). Virtual-November 5-9, 2020 | |
| EA050171B1 (ru) | Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек | |
| WO2025056005A1 (zh) | 抗tim-3抗体的药物组合物及用途 | |
| JPWO2020128864A5 (enExample) | ||
| CN118526572A (zh) | c-Met激酶抑制剂和抗PD-1抗体-TGFβRII融合蛋白的药物组合 | |
| JP2023075242A (ja) | 再発型の多発性硬化症を治療するための方法 | |
| CN120076828A (zh) | 一种含抗rankl-ngf双特异性抗体的药物组合物 | |
| WO2025093717A1 (en) | Methods of improving anti-fcrn therapies |